Stockscreener 앱 받기
22.60
3.91%
0.85
시간 외 거래:
22.60
전일 마감가:
$21.75
열려 있는:
$21.72
하루 거래량:
1.38M
Relative Volume:
1.17
시가총액:
$1.50B
수익:
$5.79M
순이익/손실:
$-199.61M
주가수익비율:
-7.5083
EPS:
-3.01
순현금흐름:
$-188.48M
1주 성능:
+8.19%
1개월 성능:
-3.21%
6개월 성능:
+11.28%
1년 성능:
-40.79%
1일 변동 폭
$21.40
$23.00
1주일 범위
$20.37
$23.00
52주 변동 폭
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
명칭
Celldex Therapeutics Inc
전화
908-200-7500
주소
53 FRONTAGE ROAD, HAMPTON
CLDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
22.60 | 1.44B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-28 | 개시 | Canaccord Genuity | Buy |
| 2025-03-20 | 개시 | Morgan Stanley | Overweight |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-10-07 | 개시 | Citigroup | Buy |
| 2024-09-30 | 개시 | Goldman | Neutral |
| 2024-09-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2023-12-20 | 개시 | TD Cowen | Outperform |
| 2023-11-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 개시 | Wells Fargo | Underweight |
| 2021-09-17 | 개시 | Jefferies | Buy |
| 2021-09-10 | 개시 | SVB Leerink | Outperform |
| 2021-07-22 | 개시 | Guggenheim | Buy |
| 2020-02-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-07 | 개시 | Aegis Capital | Buy |
| 2016-03-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2016-03-07 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-03-01 | 개시 | H.C. Wainwright | Buy |
| 2015-08-11 | 재확인 | Brean Capital | Buy |
| 2015-08-11 | 재확인 | Oppenheimer | Outperform |
| 2015-08-11 | 재확인 | ROTH Capital | Buy |
| 2015-06-02 | 재확인 | WBB Securities | Strong Buy |
| 2014-11-17 | 재확인 | ROTH Capital | Buy |
| 2014-03-04 | 재확인 | Oppenheimer | Outperform |
| 2013-07-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-03-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-02-26 | 재확인 | Oppenheimer | Outperform |
| 2013-01-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2012-10-02 | 재확인 | Oppenheimer | Outperform |
| 2012-09-14 | 재확인 | Cantor Fitzgerald | Buy |
모두보기
Celldex Therapeutics Inc 주식(CLDX)의 최신 뉴스
Analyzing recovery setups for Celldex Therapeutics Inc. investorsJuly 2025 Setups & Expert Verified Stock Movement Alerts - Newser
Live market analysis of Celldex Therapeutics Inc.Weekly Volume Report & Daily Profit Focused Screening - Newser
What technical models suggest about Celldex Therapeutics Inc.’s comebackJuly 2025 Breakouts & Free Verified High Yield Trade Plans - Newser
Custom strategy builders for tracking Celldex Therapeutics Inc.Oil Prices & Low Drawdown Investment Strategies - Newser
Is Celldex Therapeutics Inc. trending in predictive chart modelsPortfolio Growth Summary & Weekly Sector Rotation Insights - Newser
Can Celldex Therapeutics Inc. hit a new high this monthPortfolio Performance Summary & Safe Entry Trade Signal Reports - Newser
Pattern recognition hints at Celldex Therapeutics Inc. upsideMarket Rally & Weekly Stock Performance Updates - Newser
Leading vs lagging indicators on Celldex Therapeutics Inc. performanceCEO Change & Short-Term High Return Ideas - Newser
Is now a turning point for Celldex Therapeutics Inc.July 2025 Pullbacks & Risk Adjusted Buy/Sell Alerts - Newser
Will Celldex Therapeutics Inc. continue its uptrendJuly 2025 Pullbacks & Weekly Chart Analysis and Guides - Newser
Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma - GlobeNewswire Inc.
Institutional scanner results for Celldex Therapeutics Inc.Portfolio Return Report & Verified High Yield Trade Plans - Newser
How to build a dashboard for Celldex Therapeutics Inc. stockEarnings Overview Report & Precise Trade Entry Recommendations - Newser
Chart based analysis of Celldex Therapeutics Inc. trends2025 Price Momentum & Reliable Trade Execution Plans - Newser
Combining machine learning predictions for Celldex Therapeutics Inc.Gap Down & Safe Entry Point Alerts - Newser
Is Celldex Therapeutics Inc. stock bottoming outJuly 2025 Movers & High Conviction Trade Alerts - Newser
Using Bollinger Bands to evaluate Celldex Therapeutics Inc.Bull Run & Real-Time Volume Spike Alerts - Newser
Real time pattern detection on Celldex Therapeutics Inc. stockJuly 2025 Pullbacks & Real-Time Chart Pattern Alerts - Newser
Analysts Spot Bullish Divergence in Celldex Therapeutics Inc.July 2025 Earnings & Stepwise Trade Signal Implementation - newsyoung.net
Trend Dashboard Flags Celldex Therapeutics Inc. As Potential Swing TradeTrade Risk Report & Low Drawdown Momentum Ideas - 더경남뉴스
Is Celldex Therapeutics Inc. stock a top performer YTD2025 Winners & Losers & Verified Momentum Stock Alerts - theviewers.co.kr
Buy Signal for Celldex Therapeutics Inc. Stock Key Technical Indicators to WatchEarnings Beat & AI Optimized Trade Strategies - Newser
Understanding Celldex Therapeutics Inc.’s price movementJuly 2025 Pullbacks & Verified Momentum Stock Watchlist - Newser
Pullback Watch: Can Celldex Therapeutics Inc. maintain sales growthWeekly Profit Analysis & Community Trade Idea Sharing Platform - theviewers.co.kr
LifeSci Capital Maintains a Buy on Celldex Therapeutics (CLDX), Keeps the PT - MSN
Is Celldex Therapeutics Inc. Forming a Bottom Pattern2025 Analyst Calls & Risk Managed Trade Strategies - 더경남뉴스
Celldex's Strategic Pivotal Shift: From EoE Setback to GI Innovation Opportunity with Barzolvolimab - AInvest
Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track (CLDX) - Seeking Alpha
Can Celldex Therapeutics Inc. outperform in the next rallyWeekly Earnings Recap & Consistent Profit Focused Trading Strategies - kpenews.com
Celldex Phase II barzolvolimab trial in EoE to be discontinued - The Pharma Letter
H.C. Wainwright Maintains Buy Rating on Eupraxia After Celldex Data - AInvest
Celldex's EoE Setback: A Reassessment of Barzolvolimab's Strategic and Commercial Potential - AInvest
Celldex data question the role of mast cells in EOE - biocentury.com
Lowering the mast: EoE theory down after Celldex phase II - BioWorld MedTech
Using portfolio simulators with Celldex Therapeutics Inc. includedWeekly Profit Summary & Risk Managed Investment Strategies - Newser
The Strategic Reassessment of Celldex's Barzolvolimab Pipeline After EoE Setback: Identifying Resilience and Repurposing Potential in Biotech's Targeted Mast Cell Depletion Strategy - AInvest
Celldex stock price target lowered to $62 at Canaccord on EoE program halt - Investing.com Canada
Celldex Therapeutics: Citigroup Maintains Buy, PT Down to $48 from $56 - AInvest
Celldex Therapeutics Plunges 11.62%: What's Behind the Sharp Selloff? - AInvest
Celldex Bullish On Barzolvolimab Despite Study Miss - insights.citeline.com
Why Is Celldex Therapeutics Stock Falling TodayCelldex Therapeutics (NASDAQ:CLDX) - Benzinga
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
NovaBay Names New CEO, Rocket Soars As FDA Lifts Clinical Hold, Celldex Plunges, Soligenix On Watch - RTTNews
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Celldex Therapeutics Plunges 16.74% on Drug Development Halt - AInvest
Celldex Therapeutics: HC Wainwright Maintains Buy Rating, PT Down to $42 - AInvest
Celldex slides after Barzolvolimab hits target but fails to improve EoE symptoms in phase 2 trial - Seeking Alpha
Celldex Therapeutics Inc (CLDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
8.06%
자본화:
|
볼륨(24시간):